Media & Research

SYMBYX is delighted to announce today a new Parkinson’s randomised control clinical trial (RCT) in collaboration with The Hospital Research Foundation Group - Parkinson’s (THRFG) and Flinders University, Adelaide, Australia. THRFG - Parkinson’s is led by Olivia Nassaris (pictured above left). Principal investigator of the trial will be Dr Joyce Ramos, pictured (above right), of Flinders University, Adelaide. Joyce is attached to the College of Nursing and Health Sciences and is also a Research Fellow at the University of Queensland.

Australian medical technology company SYMBYX has completed its first human trial of the use of laser light therapy (photobiomodulation or PBM) to reduce the symptoms of Parkinson’s by targeting the gut-brain axis. The proof-of-concept trial showed that measures of mobility, cognition, dynamic balance, sleep, motivation, and fine motor skills of participants were all significantly improved.

It’s increasingly clear that chronic pain is often “neuroplastic” — generated by the brain in a misbegotten effort to protect us from danger....

The latest evidence comes in a peer-reviewed study just published study in the journal JAMA Psychiatry that includes striking results from a randomized controlled trial conducted at the University of Colorado at Boulder. In the study, 151 subjects with persistent back pain were randomly assigned to one of three groups. 

HOW CAN PHOTOBIOMODULATION HELP LYMPHEDEMA?

Often associated with breast cancer and/or removal of the lymph nodes, Lymphedema affects many people worldwide and starts with tingling, numbness, tightness and decreased flexibility in hands, arms, around the breast area or underarms. 

There's new hope for Parkinson's sufferers in the form of light therapy, with a clinical trial showing an improvement in the symptoms of participants.One of the participants is classically-trained pianist Chen Ong (photographed above). She is back doing what she loves after a diagnosis of Parkinson's disease two years ago. Ms Ong is now keeping the tremours at bay with the help of a [Symbyx PDCare] hand-held laser light.

SYMBYX, an Australian med-tech company developing laser light therapies to reduce Parkinson’s symptoms, said it welcomed the publication of key findings from its Adelaide clinical trial in the leading BMC Neurology Journal. The journal published results of the 52-week trial involving two groups of patients that showed improvements across a range of motor and non-motor skills. Parkinson’s South Australia (PSA) partially funded the trial.

Light Therapy on the head improved cognition in patients living with mild to moderate dementia according to the results of a clinical trial led by neurosurgeon, Jason Huang, which were published in the journal, Aging and Disease, on July 3, 2021.

Sufferers of chronic pain have long been told it’s all in their head. We now know that’s wrong, by Linda Geddes, The Guardian 28 June 2021

"To most people, pain is an unpleasant but short-lived sensation, occurring as a result of illness or injury. Although some people may experience ongoing or chronic pain, the assumption is there must be some kind of underlying physical injury, such as a crushed nerve, or an angry, inflamed joint.

Increasingly though, experts are waking up to the idea that chronic pain can occur without any obvious physical injury, or in a completely separate area of the body from the original site of tissue damage."

"I now use Photobiomodulation in combination with tailored PD exercises (Marize is a lead trainer in Melbourne for our friends over at PD Warrior) to address common barriers to patient engagement - poor sleep, constipation, bloating, nausea, reduced energy levels, muscle & joint pain, subdued mood...to name just a few. Some of these symptoms have been intractable for many years…and now they are changing for the better or have totally disappeared. This was previously unheard of.” claims Neuro Physio, Marize Newnham of Regain Life Physiotherapy in Mont Albert, Melbourne, Australia

"SYMBYX is focused on two new frontiers – using innovative laser and light devices to reduce Parkinson’s symptoms – and understanding the role of the gut microbiome in Parkinson’s and other disease models including Alzheimer’s, autism and IBS"... “the Adelaide PBM trial showed the treatment to be side-effect free, low cost and potentially clinically effective, with significant improvements in primary and secondary outcome measures. This is early stage but very promising testing."

SYMBYX’s new PDCare trial program allows Australian and NZ customers to enjoy a no obligation 30-day trial period and extended payment terms on their purchase of a PDCare laser provided they work closely with a referring health clinician.

Please note this program was extended to Canada from August 2021 also.